Insider Selling: Exicure (NASDAQ:XCUR) Major Shareholder Sells 433,332 Shares of Stock

Exicure, Inc. (NASDAQ:XCUR) major shareholder Sangsangin Investment & Securi sold 433,332 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $8.71, for a total transaction of $3,774,321.72. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Exicure Stock Performance

XCUR traded down $1.97 on Wednesday, hitting $5.32. 1,112,353 shares of the company were exchanged, compared to its average volume of 1,938,747. The stock’s fifty day moving average is $4.60 and its 200-day moving average is $5.98. Exicure, Inc. has a 12 month low of $3.10 and a 12 month high of $22.99. The company has a market cap of $33.89 million, a PE ratio of -1.44 and a beta of 4.08.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.39) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Exicure in a research report on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.